Hugel Inc
KOSDAQ:145020
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
146 600
321 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Hugel Inc
Short-Term Debt
Hugel Inc
Short-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Short-Term Debt
₩0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Short-Term Debt
₩1.6T
|
CAGR 3-Years
47%
|
CAGR 5-Years
41%
|
CAGR 10-Years
19%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Short-Term Debt
₩0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Green Cross Corp
KRX:006280
|
Short-Term Debt
₩419.3B
|
CAGR 3-Years
41%
|
CAGR 5-Years
43%
|
CAGR 10-Years
13%
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Short-Term Debt
₩250m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Short-Term Debt
₩5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Hugel Inc
Glance View
In the bustling landscape of the global biopharmaceutical market, Hugel Inc. stands out as a formidable player rooted in the dynamic world of aesthetics and medical treatments. Established in South Korea, Hugel Inc. embarked on its journey with a focus on producing botulinum toxin products, a niche that has rapidly expanded due to a surge in demand for non-surgical cosmetic procedures. The company navigated early challenges with innovative prowess, crafting a strong reputation for high-quality products that cater to a global clientele. The ethos of innovation and safety permeates its operations, enabling Hugel to diversify its portfolio and steadily gain traction in international markets, including significant footprints in Asia, Europe, and Latin America. Through a network of strategic partnerships and a robust distribution channel, Hugel not only pioneered advancements in cosmetic treatments but also cemented its status as a key contributor to the evolving aesthetics industry. The company's revenue model hinges upon the development, production, and distribution of its botulinum toxin and hyaluronic acid-based products. By focusing on research and development, Hugel enhances its capacity to innovate, delivering cutting-edge solutions that meet the rising demands of beauty-conscious consumers. Its business strategy also extends to therapeutics, exploring potential applications of its core products to address various medical conditions. Hugel's financial growth is propelled by the continuous expansion into new geographical territories and the gradual introduction of new, clinically-researched products. As the company continues to navigate the intricate regulatory landscapes of the pharmaceutical industry, it maintains an unwavering commitment to quality, ensuring that each product meets rigorous safety standards while catering to the evolving desires of its diverse customer base worldwide.
See Also
What is Hugel Inc's Short-Term Debt?
Short-Term Debt
0
KRW
Based on the financial report for Sep 30, 2024, Hugel Inc's Short-Term Debt amounts to 0 KRW.
You don't have any saved screeners yet
